EPRX: Oppenheimer Initiates
Oppenheimer initiates coverage on Eupraxia Pharmaceuticals with an Outperform rating and a price target of $17
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX ) with a Outperform rating and announces Price Target of $17.